Vancouver, Canada – April 29, 2026 – Augurex Life Sciences Corp., a leader in the development of autoimmune-based diagnostics, today announced that the company will attend the 24th Spondyloarthritis Research and Treatment Network (SPARTAN) 2026 Annual Meeting, taking place May 14 – 16 in Toronto, Canada.
The SPARTAN Annual Meeting brings together leading rheumatologists, researchers, and healthcare professionals dedicated to advancing research, diagnostics, and patient care in axial spondyloarthritis (axSpA). The meeting serves as an important forum for collaboration and discussion across the axSpA continuum of care.
Augurex looks forward to engaging with the rheumatology community and supporting discussions focused on improving the identification and management of axSpA. As part of this commitment, the company continues to advance biomarker-based diagnostic solutions designed to support earlier and more informed clinical decision-making.
Augurex’s portfolio includes SPINEstat®, a first-in-class diagnostic test designed to enable earlier identification of axSpA and help differentiate inflammatory disease from mechanical back pain, a common challenge that contributes to the 7- to 10-year diagnostic delay.
Representatives from Augurex will be available throughout the meeting and welcome the opportunity to connect with attendees to discuss developments in biomarker-driven diagnostics and their role in supporting patient care in axSpA. Those interested in meeting with the Augurex team during SPARTAN 2026 are encouraged to reach out directly to coordinate time during the conference.
For more information about the SPARTAN Annual Meeting, visit:
About Augurex
Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s 14-3-3eta blood test, available as JOINTstat® in Canada and in Great Britain, is an important tool in the diagnosis and management of rheumatoid arthritis. Analyte-specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex test, approved as SPINEstat® in Canada and Great Britain, expands Augurex’s portfolio of autoimmune diagnostic solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, which if untreated, can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn, and X.